Please enable Javascript
mCRPC
Metastatic castration-resistant prostate cancer
Advertisement
Second-line Treatment for mCRPC: Taxanes or Androgen Receptor Therapy?
Emily Menendez
mCRPC
|
March 23, 2023
A recent study compared the activity of taxanes with second-line androgen-receptor therapy in patients with mCRPC.
Read More
TRITON3: Interim OS, Efficacy of Rucaparib Versus Chemo for mCRPC
Alan H. Bryce, MD
ASCO GU Symposium 2023
|
February 17, 2023
Alan H. Bryce, MD, highlights the positive TRITON3 data for rucaparib as a new standard of care for patients with mCRPC.
View More
Treating Metastatic Prostate Cancer: Rucaparib or Physician’s Choice?
Emily Menendez
ASCO GU Symposium 2023
|
February 17, 2023
At the 2023 ASCO GU Symposium, Alan Bryce, MD, presented results from the TRITON3 study on rucaparib vs physician’s choice.
Read More
PROpel: Final OS of First-Line Abiraterone Plus Olaparib for mCRPC
Noel Clarke, MBBS, FRCS, ChM
ASCO GU Symposium 2023
|
February 17, 2023
Noel Clarke, MBBS, FRCS, ChM, explains the PROpel study design and what the overall survival data shows at data cutoff 3.
View More
TALAPRO-2: Phase 3 Results of Talazoparib Plus Enzalutamide for mCRPC
Neeraj Agarwal, MD
ASCO GU Symposium 2023
|
February 16, 2023
Neeraj Agarwal, MD, highlights the significance of TALAPRO-2 in mCRPC and the data for rPFS with respect to HRR status.
View More
Evaluation of ctDNA in Patients With CRPC, Pathogenic Germline Mutations in BRCA2
Zachary Bessette
ASCO GU Symposium 2023
|
February 16, 2023
A new study examined the relationship between pathogenic germline BRCA2 mutation and somatic change in circulating tumor DNA.
Read More
Neuroendocrine Differentiation Impacts Efficacy of First-Line Abiraterone or Docetaxel for mCRPC
Emily Menendez
ASCO GU Symposium 2023
|
February 16, 2023
A study reviewed the prognostic value of neuroendocrine differentiation in mCRPC patients receiving abiraterone or docetaxel.
Read More
Combination Versus Sequential Therapy for mCRPC
Tanya Dorff, MD
mCRPC
|
February 13, 2023
Dr. Tanya Dorff highlights the mCRPC treatment approaches worth monitoring, including sequential and combination strategies.
View More
PROpel and MAGNITUDE Trials for mCRPC
Tanya Dorff, MD
mCRPC
|
February 13, 2023
Tanya Dorff, MD, provides an overview of the latest data for PARP inhibitor plus AR-targeted agents for patients with mCRPC.
View More
Analyzing Adverse Events Related to ARSi Treatments for nmCRPC
Emily Menendez
nmCRPC
|
February 9, 2023
Existing literature on adverse events in ARSi drugs was examined to determine how the drugs’ side-effect profiles compare.
Read More
Payments for First-line mCRPC Drugs Can Vary
Emily Menendez
mCRPC
|
February 1, 2023
A study compared the gross and OOP payments for 6 different first-line mCRPC drugs during the 6 months post-treatment start.
Read More
Substantial Increase in Metastatic Prostate Cancer Cost Corresponds With Oral Therapy Approvals
Zachary Bessette
mCRPC
|
January 9, 2023
Medicare beneficiaries with metastatic prostate cancer incurred additional average costs of over $30,000 annually.
Read More
Circulating Tumor Cells May Predict Docetaxel Response in CRPC and mHSPC
Emily Menendez
mCRPC
|
January 4, 2023
Liquid biopsy of CTCs may serve as an effective prediction biomarker for docetaxel response in patients with CRPC and mHSPC.
Read More
Therapeutic Sensitivity to Standard Treatments in Patients With BRCA-Positive mCRPC
Zachary Bessette
mCRPC
|
December 15, 2022
A new study examined the efficacy of abiraterone, enzalutamide, and docetaxel in patients with BRCA-positive mCRPC.
Read More
Niraparib and Radium-223 for mCRPC: Phase 1 Study Results
Emily Menendez
mCRPC
|
December 5, 2022
Further study is needed to determine if certain biomarkers can aid in determining effectiveness and safety.
Read More
Olaparib With Abiraterone and Prednisone/Prednisolone Receives Positive Opinion for Treating mCRPC
Emily Menendez
mCRPC
|
November 17, 2022
Olaparib is the first and only PARP inhibitor to be approved for use in the EU for the treatment of prostate cancer patients.
Read More
LuPSMA Versus Cabazitaxel for mCRPC
Emily Menendez
RLT-PSMA
|
November 14, 2022
The phase 2 TheraP trial found that higher gallium-68–labeled PSMA-11-PET SUVmean had a higher chance of PSA response.
Read More
177Lu-PSMA and 225Ac-PSMA Radionuclide Therapy for mCRPC
Emily Menendez
RLT-PSMA
|
November 14, 2022
Studies have investigated the effects of 177Lu-PSMA and 225Ac-PSMA RNT in mCRPC patients, with promising treatment results.
Read More
Olaparib, Cediranib Improved rPFS in mCRPC, But Upped Toxicities
Leah Lawrence
mCRPC
|
October 25, 2022
Olaparib with cediranib significantly improved rPFS in men with mCRPC, but was associated with an increase in adverse events.
Read More
Updated Results From the Phase 3 PROpel Trial
Akhil Abraham Saji, MD
Journal
|
October 24, 2022
Results from the phase 3 PROpel trial on abiraterone + olaparib vs abiraterone + placebo as first-line therapy for MCRPC
Read More
Load More
Advertisement
Advertisement
Advertisement